SEARCH

SEARCH BY CITATION

References

  • 1
    Graham DY & Smith JL. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 1988; 83: 1081 4.
  • 2
    Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Arthritis Rheum 1995; 1: 5 18.
  • 3
    Smalley WE & Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin N Am 1996; 25: 373 96.
  • 4
    Manniche C, Malchow Moller A, Andersen JR, et al. Randomized study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Gut 1987; 28: 226 9.
  • 5
    Roth S, Agrawal N, Mahowald M, Montego M, Robbins D. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989; 149: 775 9.
  • 6
    Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69 75.
  • 7
    Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991; 32: 252 5.
  • 8
    Bianchi Porro G & Lazzaroni M. Prevention and treatment of non-steroidal gastroduodenal lesions. Eur J Gastroenterol Hepatol 1993; 5: 420 32.
  • 9
    Kawkey CJ, Swannell AJ, Eriksson S, et al. Benefits of omeprazole over misoprostol in healing NSAID-associated ulcers. Gut 1996; 38(Suppl. 1): A39(Abstract).
  • 10
    Hawkey CJ, Swannell AJ, Yeomans ND, Carlsson M, Floren I, Jallinder M. Increased effectiveness of omeprazole compared to ranitidine in nonsteroidal anti-inflammatory drug (NSAID) users with reference to H. pylori status. Gut 1996; 39(Suppl. 3): A149(Abstract).
  • 11
    Caruso I & Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. Br Med J 1980; 280: 75 8.
  • 12
    Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359 63.
  • 13
    Amstrong CP & Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527 32.
  • 14
    O’laughlin JC, Silvoso GR, Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. Dig Dis Sci 1982; 27: 976 80.
  • 15
    Hollander D, Tarnawski A, Gergely H, Zipser RS. Sucralfate protection of the gastric mucosa against ethanol-induced injury: a prostaglandin-mediated process? Scand J Gastroenterol 1984; 19(Suppl. 101): 97 102.
  • 16
    Shepherd HA, Fine D, Hillier K, Jewell R, Cox N. Effect of sucralfate and cimetidine on rheumatoid patients with active gastroduodenal lesions who are taking nonsteroidal anti-inflammatory drugs. Am J Med 1989; 86(Suppl. 6A): 49 54.
  • 17
    Caldwell JR, Roth SH, Wu WC , et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med 1987; 83(Suppl. 3B): 74 82.
  • 18
    Eriksson S, Lingstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2 receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux esophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 467 75.
  • 19
    Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996; 334: 1435 6.
  • 20
    Oddsson E, Gudjonsson H, Thjodleifsson B. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 1992; 27: 1045 8.
  • 21
    Clayton NM, Oakley IO, Williams LV, Trevethick MA. The role of acid in the pathogenesis of indomethacin-induced gastric antral ulcers in rat. Aliment Pharmacol Ther 1996; 10: 339 45.
  • 22
    Christie JMI, McNulty CAM, Sheperd NA, Valori RM. Is saliva serology useful for the diagnosis of Helicobacter pylori? Gut 1996; 39: 27 30.
  • 23
    Wyatt JI & Rathbone BJ. The role of serology in the diagnosis of Campylobacter pylori infection. Scand J Gastroenterol 1989; 24: S27 34.
  • 24
    Veenendall RA, Pena AS, Mejiar IL, et al. Longterm serological surveillance after treatment of Helicobacter pylori infection. Gut 1991; 32: 1291 4.
  • 25
    Loeb OS, Talley NJ, Ahlquist DA, et al. Long-term nonsteroidal anti-inflammatory drug use and gastrointestinal injury. The role of Helicobacter pylori Gastroenterology 1992; 102: 1899 903.
  • 26
    Upadhayay R, Howatson A, McKinlay A, et al. Campylobacter pylori-associated gastritis in patients with rheumatoid arthritis taking nonsteroidal anti-inflammatory drugs . Br J Rheumatol 1988; 27: 113 16.
  • 27
    Lanza FL, Evans DG, Graham DY. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. Am J Gastroenterol 1991; 86: 735 7.
  • 28
    Kim JG & Graham DY and the Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol 1994; 89: 203 7.
  • 29
    Shallcross TM, Rathbone BJ, Wyatt JI, Heatley RV. Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1990; 4: 515 22.
  • 30
    Taha AS, Fraser WD, Kelly RW, Gemme CG, Lee FD, Russel RI. Inhibition of human gastric cyclic AMP production by Helicobacter pylori protein—possible involvement of mucosal prostaglandin E2 . Aliment Pharmacol Ther 1991; 5: 379 89.
  • 31
    Zeidler H. Epidemiology and economics of NSAID-induced gastropathy Scand J Rheumatol 1992; 92: 3 8.